The market is segmented based on Segmentation, By Indication (Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others), Drug Glass (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), Route of Administration (Oral, Injection, Transdermal), End- User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Neurodegenerative Disorder Therapeutics Market size was valued at USD 17.30 USD Billion in 2024.
The Global Neurodegenerative Disorder Therapeutics Market is projected to grow at a CAGR of 5.67% during the forecast period of 2025 to 2032.
The major players operating in the market include Biogen , Merck Sharp & Dohme Corp , Novartis AG , Teva Pharmaceutical Industries Ltd. , Orion Corporation , UCB S.A. , ACADIA Pharmaceuticals Inc. , Mitsubishi Chemical Group Corporation , H. Lundbeck A/S , Denali Therapeutics , Aquinnah Pharmaceuticals , Prevail Therapeutics , AZTherapiesInc. .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.